46 completed, 6 terminated, 4 active not recruiting, 3 recruiting. 18 Not applicable, 17 Phase 1, 17 Phase 2, 8 Phase 3, 5 Phase 4.
Follow Triiodothyronine: new trials by email Literature Review of Triiodothyronine trials Research Report on Triiodothyronine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| T4/T3 Therapy in Hypothyroidism Liothyronine (L-T3), Levothyroxine Sodium (LT4) Tablets, Liothyronine (LT3) placebo - Hypothyroidism Primary | Phase 2 | Not yet recruiting | University of Pennsylvania | 60 | 2026-11-01 | 2026-08-20 |
| Short-Term Effects of Manual Therapy Prior to Neuromotor Therapy in Children With Cerebral Palsy Manual Therapy (T1 & T3) - Cerebral Palsy (CP), Unilateral Spastic Cerebral Palsy | Not applicable | Recruiting | LIFE - Research and Care Institute - Santa Lucia IRCCS | 20 | 2026-10-15 | 2026-10-28 |
| Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy Euthyrox (levothyroxine), Cytomel (liothyronine) - Differentiated Thyroid Cancer, Thyroid Cancer | Not yet recruiting | University Medical Center Groningen | 40 | 2026-09-01 | 2026-02-10 | |
| Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease Liothyronine (L-T3), Bevacizumab, Irinotecan - Medulloblastoma, Medulloblastoma, Childhood | Phase 1 / Phase 2 | Recruiting | Sabine Mueller, MD, PhD | 69 | 2026-08-21 | 2026-09-28 |
| Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes Testosterone Enanthate, Testosterone Cypionate, Testosterone Propionate - Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes | Not applicable | Enrolling by invitation | Enhanced Emirates Limited | 60 | 2026-03-12 | 2026-05-06 |
| Combining Stellate Ganglion and T2 and T3 Radiofrequency Ablation on Post-mastectomy Complex Regional Pain Syndrome Radiofrequency stellate ganglion block using ultrasound guidance (SGB), Radiofrequency thoracic (T2, T3) paravertebral block under fluoroscopic guidance (TPVB), Combined radiofrequency of stellate ganglion block plus thoracic T2, T3 paravertebral block - Stellate Ganglion, Radiofrequency Ablation | Not applicable | Unknown | National Cancer Institute, Egypt | 150 | 2023-10-07 | 2023-10-10 |
| Effects of Triiodothyronine (T3) in Ischemic Heart Failure Thyroid hormone T3, Control Group - Heart Failure | Phase 1 | Completed | Emory University | 14 | 2022-12-02 | 2026-08-04 |
| LT4/LT3 Combination Therapy Versus LT4 Monotherapy in Patients with Autoimmune Hypothyroidism. LT3 (liothyronine), Placebo - Autoimmune Hypothyroidism | Phase 3 | Recruiting | M. Medici | 600 | 2022-10-07 | 2025-02-26 |
| Thyroid Hormone Supplementation in Patients With Septic Shock triiodothyronine - Euthyroid Sick Syndromes, Septic Shock | Phase 2 | Completed | Cantonal Hospital Zenica | 108 | 2022-05-01 | 2023-09-28 |
| 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma Irinotecan, Temozolomide, Bevacizumab - Recurrent Medulloblastoma, Recurrent Ependymoma | Phase 2 | Active not recruiting | Pediatric Brain Tumor Consortium | 62 | 2022-04-04 | 2026-07-28 |
| Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma Liothyronine, Lomustine, Methimazole - Recurrent Glioblastoma, Recurrent Gliosarcoma | Early Phase 1 | Withdrawn | Emory University | 2021-10-20 | 2022-12-02 | |
| Energy Metabolism in Thyroidectomized Patients Levothyroxine, Liothyronine, Placebo - Thyroid Goiter, Hypothyroidism | Phase 2 | Completed | Virginia Commonwealth University | 13 | 2020-10-28 | 2024-06-14 |
| Treatment of ARDS With Instilled T3 Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation., Non-intervention - ARDS, Human, Lung, Wet | Phase 2 | Active not recruiting | University of Minnesota | 68 | 2020-03-30 | 2026-04-07 |
| Developing Oral LT3 Therapy for Heart Failure - HFpEF liothyronine, Placebo - Heart Failure With Preserved Ejection Fraction, Low Triiodothyronine Syndrome | Phase 1 / Phase 2 | Completed | University of Pennsylvania | 28 | 2020-03-08 | 2025-01-08 |
| Developing Oral LT3 Therapy for Heart Failure - HFrEF Liothyronine, Placebo - Heart Failure With Reduced Ejection Fraction (HFrEF), Low T3 Syndrome | Phase 1 / Phase 2 | Completed | University of Pennsylvania | 28 | 2020-02-11 | 2024-12-24 |
| A Study in Healthy Men That Tests if Taking BI 1265162 by Mouth, Intravenously, or Inhaled Influences the Amount of BI 1265162 in the Blood BI 1265162 (T1), BI 1265162 (T2), BI 1265162 (R) - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 12 | 2019-04-23 | 2022-07-06 |
| Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma Triiodothyronine (T3) - Metastatic Breast Cancer, Thyroid Dysfunction | Phase 2 | Terminated | Aultman Health Foundation | 7 | 2019-03-01 | 2022-05-13 |
| A Study in Healthy People to Measure the Amount of BI 655130 in the Blood After Injecting Different Doses Into Different Parts of the Body R - Low dose of BI 655130, T1 - Low dose of BI 655130, T2 - Low dose of BI 655130 - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 48 | 2018-08-16 | 2025-10-20 |
| Identification of Non-responders to Levothyroxine Therapy Levothyroxin, Liothyronine - Hypothyroidism, Biomarkers | Phase 2 | Completed | Oslo University Hospital | 69 | 2018-08-14 | 2021-03-17 |
| PREPA PREvention of Loss of Autonomy Multidimensional assessments, Multicomponent group-based and supervised exercise program, Follow-up at T3 + 6 months and T3 + 12 months - Mobility Limitation, Physical Activity | Not applicable | Active not recruiting | Hospices Civils de Lyon | 530 | 2018-07-10 | 2025-09-09 |
Showing 20 of 66. Sign in to see all of them.
Hypothyroidism (12) · Euthyroid Sick Syndromes (8) · Depressive Disorder, Major (6) · Depression (5) · Thyroid Neoplasms (5) · Heart Defects, Congenital (4) · Heart Failure (4) · Thyroid Diseases (4) · Bipolar Disorder (2) · Breast Neoplasms (2) · Depressive Disorder, Treatment-Resistant (2) · Medulloblastoma (2) · Motor Activity (2) · Adenocarcinoma, Follicular (1) · Agnosia (1)
University of Pennsylvania (4) · Emory University (3) · National Cardiovascular Center Harapan Kita Hospital Indonesia (3) · Boehringer Ingelheim (2) · Hadassah Medical Organization (2) · Hospices Civils de Lyon (2) · Ipe, LLC (2) · Mayo Clinic (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Northwell Health (2) · Stanford University (2) · Virginia Commonwealth University (2) · Aultman Health Foundation (1) · Aydin Adnan Menderes University (1) · Azienda USL Modena (1)
United States (35) · Netherlands (4) · Germany (3) · Indonesia (3) · Denmark (2) · France (2) · Israel (2) · Italy (2) · South Korea (2) · Belgium (1) · Bosnia and Herzegovina (1) · Canada (1) · Egypt (1) · Norway (1) · Turkey (Türkiye) (1)
Anne R Cappola, MD,ScM (2) · Eva M Marwali, MD (2) · Michael Portman, MD (2) · A. John Rush, MD (1) · Amy L Drendel, DO (1) · Angeliki M Stamatouli, MD (1) · Anne R Cappola, MD, ScM (1) · Arshed A. Quyyumi, MD (1) · Bernard Lerer, MD (1) · Birte Nygaard (1) · Boadie W Dunlop, MD, MS (1) · Brian J. Davis, M.D. (1) · Christopher L Sola, D.O. (1)
PMID 20837917, PMID 40877763, PMID 16086620, PMID 16390886, PMID 16426099, PMID 16457894, PMID 16551710, PMID 16554525, PMID 16554526, PMID 16566612, PMID 16566901, PMID 16636629, PMID 16642436, PMID 16690084, PMID 16754414, PMID 16816220, PMID 16824617, PMID 16946176, PMID 16946177, PMID 17074942, PMID 17091129, PMID 17195602, PMID 17302619, PMID 17548749, PMID 17711927, PMID 18162025, PMID 18206856, PMID 18678792, PMID 18681756, PMID 19026268, PMID 19192454, PMID 19339358, PMID 19341509, PMID 19460188, PMID 19493369, PMID 19945804, PMID 20010317, PMID 20194481, PMID 20447070, PMID 21114950, PMID 21216475, PMID 21518864, PMID 21865366, PMID 21929846, PMID 21964277, PMID 22008447, PMID 22057975, PMID 22884879, PMID 22933451, PMID 22964160
2018 (2), R61HL146390 (2), 2015 (1), 2016 (1), 2017 (1), K24AG042765 (1), P30CA138292 (1), P50CA091956 (1), R01DK137207 (1), R01MH056946 (1), R21DK122310 (1), UM1CA081457 (1)